These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 2328211)
1. Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response. Maitland JA; Millar BC; Bell JB; Montes A; Treleaven J; Gore ME; McElwain TJ Br J Cancer; 1990 Mar; 61(3):429-33. PubMed ID: 2328211 [TBL] [Abstract][Full Text] [Related]
2. Increase in clonogenic tumour cells in bone marrow of patients with multiple myeloma treated with vincristine, doxorubicin, and methylprednisolone. Bell JB; Millar BC; Maitland JA; Nandi A; Gore M; McElwain TJ Lancet; 1988 Oct; 2(8617):931-3. PubMed ID: 2902382 [TBL] [Abstract][Full Text] [Related]
3. Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone. Bell JB; Millar BC; Montes-Borinaga A; Joffe JK; Cunningham D; Mansi J; Treleaven J; Viner C; McElwain TJ Hematol Oncol; 1990; 8(6):347-53. PubMed ID: 2286358 [TBL] [Abstract][Full Text] [Related]
4. In vitro studies of ways to overcome resistance to VAMP--high dose melphalan in the treatment of multiple myeloma. Millar BC; Bell JB; Maitland JA; Zuiable A; Gore ME; Selby PJ; McElwain TJ Br J Haematol; 1989 Feb; 71(2):213-22. PubMed ID: 2923807 [TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 is a cofactor for the growth of myeloid cells from human bone marrow aspirates but does not affect the clonogenicity of myeloma cells in vitro. Borinaga AM; Millar BC; Bell JB; Joffe JK; Millar JL; Gooding R; Riches P; McElwain TJ Br J Haematol; 1990 Dec; 76(4):476-83. PubMed ID: 2265109 [TBL] [Abstract][Full Text] [Related]
6. VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma. McElwain TJ; Gore ME; Meldrum M; Viner C; Judson IR; Malpas JS Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():109-12. PubMed ID: 2697419 [TBL] [Abstract][Full Text] [Related]
8. The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates. Millar BC; Bell JB; Barfoot R; Everard M Br J Cancer; 1995 Feb; 71(2):259-64. PubMed ID: 7841038 [TBL] [Abstract][Full Text] [Related]
10. Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment. Takemori N; Kondo K; Kawamura T; Imai K; Sakurai H; Sato T Am J Hematol; 2001 Jan; 66(1):62-3. PubMed ID: 11426497 [TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy of multiple myeloma]. Golenkov AK Sov Med; 1991; (3):43-6. PubMed ID: 1882290 [No Abstract] [Full Text] [Related]
12. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol. Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554 [No Abstract] [Full Text] [Related]
14. Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft. Sirohi B; Powles R; Rudin C; Singhal S; Kulkarni S; Saso R; Horton C; Mehta J; Treleaven J Hematology; 2005 Oct; 10(5):361-4. PubMed ID: 16203605 [TBL] [Abstract][Full Text] [Related]
15. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness. Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662 [TBL] [Abstract][Full Text] [Related]
16. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol]. Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962 [TBL] [Abstract][Full Text] [Related]
17. Intermediate dose of intravenous melphalan in advanced multiple myeloma. Tsakanikas S; Papanastasiou K; Stamatelou M; Maniatis A Oncology; 1991; 48(5):369-71. PubMed ID: 1745483 [TBL] [Abstract][Full Text] [Related]
18. Meningeal myeloma in the absence of systemic disease, and as the initial feature of disease progression. Somers LJ; Shaw B; Lyn BE; McMillan AM; Mahendra P Clin Lab Haematol; 1998 Jun; 20(3):189-90. PubMed ID: 9681237 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793 [TBL] [Abstract][Full Text] [Related]
20. Intensive treatment of multiple myeloma and criteria for complete remission. Gore ME; Selby PJ; Viner C; Clark PI; Meldrum M; Millar B; Bell J; Maitland JA; Milan S; Judson IR Lancet; 1989 Oct; 2(8668):879-82. PubMed ID: 2571812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]